China Mobile and ZTE win the Asia Mobile Award 2025 with AI-driven 5G cloudified core network
China Mobile and ZTE have developed the innovative AI-driven green and energy-saving 5G cloudified core network project to reduce the energy consumption and improve the network performance and operation efficiency
The AI-driven green and energy-saving 5G cloudified core network innovative and replicable solution helps operators reduce OPEX and CAPEX while achieving significant energy saving effect
SHANGHAI, June 20, 2025 /CNW/ -- ZTE Corporation (0763.HK / 000063.SZ), a global leading provider of integrated information and communication technology solutions, in partnership with China Mobile, has earned "Best Mobile Innovation for Climate Action in Asia" award for their AI-driven green and energy-saving 5G cloudified core network innovation project at the Asia Mobile Awards(AMOs) during MWC Shanghai 2025.
Energy conservation, emission reduction and green transformation in the communications industry are key issues in the global shift towards green and sustainable development.
The innovative AI-driven green and energy-saving 5G cloudified core network project aims to significantly reduce the energy consumption of the 5G core network while enhancing network performance and operation efficiency through the innovative cloud-native architecture and intelligent energy-saving technology. Leveraging ZTE's leading Intelligent 5G core network solutions and China Mobile's extensive experience in green communications, this project successfully achieves energy efficiency optimization and carbon emission reduction of 5G core network, providing operators with efficient and environmentally-friendly 5G core network deployment solutions.
The AI-driven green and energy-saving 5G cloudified core network innovation project not only helps operators reduce OPEX and CAPEX, but also provides replicable solutions for the sustainable development of global 5G core networks. To date, this project has been deployed across multiple provinces of China, achieving significant energy savings.
Moving forward, ZTE will further its collaboration with China Mobile to promote the application of green and energy-saving technologies in a wider range of network systems. Both parties will work together with global partners to advance the green and intelligent development of 5G networks, with great commitment to the sustainable development of the global communications industry.
ABOUT ZTE:
ZTE connects the world with continuous innovation for a better future. The company provides innovative technologies and integrated solutions, and its portfolio spans communication networks, computing infrastructure, industry digital solutions, and personal and home smart terminals. Serving over a quarter of the world's population, ZTE is dedicated to leading globally in connectivity and intelligent computing, enabling communication and trust everywhere. ZTE is listed on both the Hong Kong and Shenzhen Stock Exchanges.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
44 minutes ago
- Cision Canada
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
VANCOUVER, BC, June 20, 2025 /CNW/ -- USA News Group News Commentary – The costs of cancer drugs is skyrocketing, according to a recent report from Bloomberg. Analysts at Nova One Advisor estimate that the global oncology drugs market will grow at a 7.4% CAGR through to US$366.24 billion by 2034. Help doesn't appear to be coming from the public sector, as reports state that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For investors to note, plenty of oncology innovators have provided recent developments, including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Immuneering Corporation (NASDAQ: IMRX), GRAIL, Inc. (NASDAQ: GRAL), Intensity Therapeutics, Inc. (NASDAQ: INTS), and Relay Therapeutics, Inc. (NASDAQ: RLAY). The global oncology market is expected to see strong growth over the next decade, with ResearchAndMarkets forecasting it to reach US$866.1 billion by 2034 at a 10.8% CAGR. A separate estimate from Vision Research Reports projects the market will surpass US$903.81 billion by the same year, growing at a 10.9% CAGR. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has entered a new phase of leadership with the appointment of Jared Kelly as Chief Executive Officer and member of the Board. Kelly brings a background in high-stakes biotech transactions and strategic immuno-oncology development, positioning him to guide the company through its next stage of clinical and business evolution. Before joining Oncolytics, Kelly served as General Counsel at Ambrx Biopharma, where he played a key role in its $2 billion acquisition by Johnson & Johnson. His earlier work includes advising life sciences firms on licensing, partnerships, and M&A while at Kirkland & Ellis LLP and Lowenstein Sandler LLP. Now leading Oncolytics, he steps into a company advancing pelareorep, a virus-based immunotherapeutic designed to work synergistically with checkpoint inhibitors and other agents across a range of solid and blood cancers. "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients," said Jared Kelly, CEO of Oncolytics Biotech. "With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders." Kelly's appointment signals a clear strategic focus: advancing pelareorep toward key late-stage milestones through a capital-conscious approach that remains open to strategic collaboration. Pelareorep currently holds FDA Fast Track designation for both metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) —a rare dual recognition that underscores its regulatory momentum. Across multiple studies, the virus-based therapy has demonstrated consistent immune activation, broad combinability with checkpoint inhibitors and chemotherapies, and encouraging response rates in challenging cancer types. In mPDAC, pelareorep has achieved over 60% objective response rates in tumor-evaluable patients across Phase 1 and 2 trials—more than double what's typically seen in historical benchmarks. Separate analyses also reported two-year survival rates four to six times higher than control arms or prior studies. In HR+/HER2- mBC, two randomized Phase 2 trials (IND-213 and BRACELET-1) showed survival benefits supportive of further investigation. Meanwhile, a Phase 2 cohort in anal cancer pairing pelareorep with a checkpoint inhibitor reported partial or complete responses in nearly half of evaluable patients—substantially higher than historical norms for monotherapy in this setting. "Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date," said Wayne Pisano, Chair of the Board and outgoing Interim CEO of Oncolytics. "We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors." Kelly's compensation package includes equity grants and milestone-linked incentives tied to future financings and potential strategic transactions—aligning leadership priorities with long-term shareholder interests. The structure signals a commitment to advancing both clinical and corporate goals while preserving balance sheet discipline and maintaining appeal for potential partners. With multiple cohorts progressing in the GOBLET study—including those in pancreatic and anal cancer supported by external funding and regulatory engagement— Oncolytics is positioned to move forward with a combination of scientific momentum, financial agility, and renewed strategic focus. In other recent industry developments and happenings in the market include: Immuneering Corporation (NASDAQ: IMRX) reported positive Phase 2a data for atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients. At six months, the study showed 94% overall survival and 72% progression-free survival in 34 patients, with no median OS or PFS reached yet. "These exceptional data demonstrate the potential of atebimetinib plus mGnP to dramatically extend the lives of patients with advanced pancreatic cancer," said Ben Zeskind, Ph.D., Co-founder and CEO of Immuneering. "Our ultimate goal is to help cancer patients outlive their disease, and today's announcement represents an important milestone on that journey." The combination also demonstrated a 39% overall response rate, an 81% disease control rate, and a notably favorable tolerability profile. Many patients experienced deep, durable tumor regressions, including lesions rendered undetectable. The regimen was well tolerated, with an adverse event profile suggesting potential best-in-class positioning among MEK inhibitors. GRAIL, Inc. (NASDAQ: GRAL), recently announced strong top-line results from the PATHFINDER 2 registrational study evaluating its Galleri® multi-cancer early detection test in over 25,000 adults. "We are delighted to see very encouraging performance of the Galleri MCED test as a cancer screening tool in broad intended use populations of asymptomatic adults over 50 years of age in both the PATHFINDER 2 study and the NHS-Galleri trial's prevalent screening round," said Josh Ofman, MD, MSHS, President at GRAIL. "We would like to extend our sincere gratitude to all of the participants and investigators in both of these pivotal studies, who are collectively helping to realize the potential of this groundbreaking technology for population-scale multi-cancer early detection and move the field forward." The study showed a substantially higher positive predictive value (PPV) compared to the original PATHFINDER trial, with consistent specificity and cancer signal origin accuracy, and no serious safety concerns reported. GRAIL plans to submit these results to the FDA as part of its ongoing premarket approval process under Breakthrough Device Designation. Intensity Therapeutics, Inc. (NASDAQ: INTS) announced that the first patients in its ongoing Phase 2 INVINCIBLE-4 trial achieved high levels of tumor necrosis within eight days of receiving two doses of INT230-6, before starting standard-of-care immunochemotherapy for triple-negative breast cancer (TNBC). "We are excited to see that INT230-6 is achieving meaningful levels of necrosis in patients with evidence of immune activation," said Lewis H. Bender, President and CEO of Intensity. "TNBC patients risk their lives to achieve a pCR, and about forty percent fail to achieve the desired result." MRI scans showed substantial tumor destruction and inflammation, suggesting immune activation following direct intratumoral injection. The randomized study compares INT230-6 followed by standard treatment versus standard treatment alone, with pathological complete response (pCR) as the primary endpoint. Relay Therapeutics, Inc. (NASDAQ: RLAY) reported updated interim data from its Phase 1/2 study of RLY-2608 plus fulvestrant, showing a median progression-free survival (PFS) of 11.0 months in second-line patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. "We are encouraged by the consistency of these updated RLY-2608 + fulvestrant data, which continue to show the potential benefit of a mutant-selective PI3Kα inhibitor for improving both the tolerability profile and progression free survival compared to standard of care," said Don Bergstrom, M.D., Ph.D., President of R&D at Relay Therapeutics. "We look forward to starting the first mutant-selective PI3Kα Phase 3 trial, ReDiscover-2, in the middle of this year." Among patients at the recommended Phase 3 dose, the clinical benefit rate reached 67%, and 39% had confirmed partial responses, with notably higher response rates in those with kinase mutations. The combination maintained a favorable tolerability profile, with low rates of high-grade adverse events and minimal treatment discontinuations. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Cision Canada
an hour ago
- Cision Canada
Reklaim Expands 'Protect' to Include California Opt-Outs, Ad Tech Removal, and Family Protection
Subscribers' data is now automatically removed from California-registered data brokers, as well as enterprise and DSP platforms TORONTO, June 20, 2025 /CNW/ - Reklaim Ltd. (TSXV: MYID) (OTC: MYIDF) ("Reklaim" or the "Company"), a leader in consumer data privacy and compliant data monetization, today announced a significant update to Reklaim Protect, its privacy subscription service that helps users shrink their digital footprint. With this latest release, Reklaim Protect now automatically removes subscriber data from companies listed in California's official data broker registry, as well as enterprise data platforms and demand-side platforms (DSP s) used in digital advertising. These new capabilities further strengthen Reklaim's position as a privacy-first alternative for consumers who want to opt out of the data economy and reduce the availability of their information for sale, targeting, or unauthorized use. "Removing your data from these platforms is about cutting off the source," said Neil Sweeney, Founder and CEO of Reklaim. "Brokers, fraudsters, and bad actors all rely on the same data supply to power their models. If you don't proactively reduce your footprint, your information remains exposed and in circulation. By integrating the California registry, we're cutting subscribers off from one of the largest data pipelines in the world." Key Features of Reklaim Protect (V2) California Data Broker Registry Opt-Out Reklaim subscribers' data is now automatically removed from data brokers listed in California's official registry, the largest of its kind in the world, with a single digital signature inside the Reklaim app. This step leverages state privacy laws to disconnect consumers from some of the most active and persistent data sellers in the U.S. View the official registry ➝ Enterprise & DSP Data Removal Reklaim now facilitates opt-outs from enterprise data platforms and demand-side platforms (DSPs) used by advertisers to profile and target consumers, helping reduce unwanted surveillance and behavioural tracking. Family-Wide Monitoring Protect Subscribers, who are also members of Reklaim Rewards, can also monitor up to 10 verified email addresses for dark web breaches, extending protection to family members and close contacts. These enhancements build on the original features of Reklaim Protect, which include: Reklaim Protect is available to Reklaim subscribers in Canada and the United States, offering a 14-day free trial and ongoing access for just $1/month or $10/year. The service is fully integrated into the Reklaim mobile and web app experience.
CTV News
an hour ago
- CTV News
Global equity funds log biggest outflows in three months on Mideast tensions
Flames rise from an oil storage facility after it appeared to have been hit by an Israeli strike in Tehran, Iran, early Sunday, June 15, 2025. (AP Photo/Vahid Salemi) Global equity funds recorded net outflows of $19.82 billion for the week ended June 18, the largest in three months, as escalating Middle East tensions and lingering uncertainty over U.S. trade policies dampened investor sentiment. Investors divested a net US$19.82 billion from global equity funds during the week, according to LSEG Lipper data. U.S. equity funds led regional outflows with net sales of US$18.43 billion, their steepest withdrawal in three months. Asia saw outflows of US$2.86 billion, while Europe recorded net inflows of US$640 million. Despite broader outflows, equity sectoral funds attracted US$573 million in net inflows, the fourth straight week of purchases. Tech and industrials led sectoral gains with a net US$1.5 billion and US$752 million in inflows, respectively, while financials saw nearly US$1.5 billion of net outflows. Global bond funds were popular for the ninth consecutive week, attracting around US$13.13 billion in net inflows. Euro-denominated bond funds drew US$3.07 billion in net inflows, following US$7.97 billion of inflows in the prior week. Investors also lapped up short-term and high-yield bond funds, which garnered US$2.93 billion and US$1.94 billion, respectively. In contrast, investors pulled out a net US$2.7 billion from money market funds after about US$4.1 billion of net sales in the previous week. Demand for gold and precious metals commodity funds surged to the highest in two months during the week as these funds received US$2.84 billion in net inflows. Emerging market bond funds attracted net inflows of US$2.5 billion, with demand extending to an eighth successive week. Investors, however, withdrew US$234 million from equity funds, according to data for 29,726 funds. --- Reporting by Gaurav Dogra in Bengaluru; Editing by Harikrishnan Nair
